Life Extension Magazine October 2010
Low Testosterone Promotes Abdominal Obesity in Aging Men
By Julius Goepp, MD
By Julius Goepp, MD
Testosterone Levels—Early Warning of Impending Disaster
The association of declining testosterone levels with obesity, the metabolic syndrome, and cardiovascular disease is so strong that many experts now recommend checking testosterone levels to provide early warning of the metabolic syndrome.1
Testosterone deficiency has been found to be a significant and independent risk factor for metabolic syndrome, even in non-obese older men.31 It causes not only increased fat mass, but also triggers elevations in fasting insulin levels, a late marker of developing metabolic syndrome.7,32
The association of low testosterone levels with metabolic syndrome is independent of age—that is, even younger men with low testosterone are immediately at increased risk for the syndrome.33 Somewhat surprisingly, the association is also independent of BMI, pointing to testosterone’s multiple effects on regulation of glucose, insulin, and lipid metabolism.34 It has recently been proposed, in fact, that low testosterone levels be included in the very definition of the metabolic syndrome, because of the consistency with which it occurs.35
There’s an obvious implication here. Subtle deficiencies in testosterone may be present long before obesity and other more obvious manifestations of the metabolic syndrome become evident.34 That makes it vital for all men, not just the overweight or obese, to have testosterone levels checked regularly by a reliable laboratory. Be sure that both total testosterone and free testosterone are ordered—both have been associated with metabolic syndrome.35
When having your blood tested for total and free testosterone, make sure you also order tests for PSA to rule out existing prostate cancer, estradiol to determine whether you need to take an aromatase inhibiting drug in case estrogen levels are too high, and a CBC/chemistry test to measure liver function and blood cell counts. All of these tests are included in the new Male Weight Loss Blood Test Panel described at the end of this article.
Restoring Healthy Testosterone Levels
What should you do if your testosterone level comes back low? There’s a growing body of evidence suggesting that careful testosterone replacement therapy is protective against many features of the metabolic syndrome and can enhance blood sugar control.36 Given early enough, testosterone therapy may slow or even halt the progression from early metabolic syndrome to diabetes or cardiovascular disease.17 In one study of diabetic men with low testosterone, oral treatment improved their glucose control and decreased their abdominal obesity. A beneficial side effect was reduction in erectile dysfunction.6 Other placebo-controlled studies have shown decreases in whole body, total, and subcutaneous abdominal fat mass, accompanied by increases in lean body mass, as a result of testosterone therapy.8
Of course it’s important to check and to follow testosterone levels when considering treatment. Achieving testosterone levels within the existing reference ranges may not be sufficient to combat obesity and metabolic syndrome. Some testosterone-dependent biological functions require higher levels than others, and those thresholds differ among men.37
Finally, a word about testosterone therapy and the risk of prostate cancer. For decades we believed (and some still do) that higher serum testosterone concentrations contribute to the risk of prostate cancer. More recently, considerable data have emerged suggesting a more complex picture, and indicating that in fact testosterone therapy may not be nearly as risky as once assumed.38 In fact, according to Dr. Abraham Morgentaler of Harvard’s Beth Israel Deaconess Medical Center, “One of the more interesting changes over the last several years has been the growing acceptance of the use of testosterone therapy in men with a prior history of prostate cancer, with early data indicating minimal risk of cancer recurrence or progression.”38 Other experts in the field agree that the risks of testosterone therapy are often exaggerated and should not outweigh the benefits of treatment.21
Indeed, Dr. Morgentaler goes on to note, new evidence suggests that it is not high, but low serum testosterone that is responsible for many features of prostate cancer risk.38 Since we now know that low testosterone causes obesity, and we further know that obesity is a risk factor for cancer,39,40 there is certainly a logical basis for the idea that low testosterone is indirectly a cancer risk factor.
Testosterone and body fat content have an intricate and bidirectional relationship. Excess body fat causes low testosterone, but low testosterone also causes excess body fat. Testosterone regulates many facets of energy balance, with an especially powerful impact on glucose, insulin, and fat metabolism. The deadly results of low testosterone therefore exceed simply causing obesity. Low testosterone also dramatically raises men’s risk for the metabolic syndrome, a major health threat for anyone at or beyond middle age. Experts now recommend regular testing for any man at risk for low testosterone, including aging men.1 If your testosterone levels prove to be low, you should consider testosterone treatment in consultation with a physician.
To order the new Male Life Extension Weight Loss Blood Test Panel at the special introductory price of only $249, call 1-800-208-3444 or log on to www.lef.org/blood. A description of the many important tests included in the Male Life Extension Weight Loss Blood Test Panel can be found on www.lef.org/blood
If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at
1. Spark RF. Testosterone, diabetes mellitus, and the metabolic syndrome. Curr Urol Rep. 2007 Nov;8(6):467-71.
2. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004 May;27(5):1036-41.
3. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009 Feb;41(1):7-13.
4. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010 Jun;33(6):1186-92.
5. Available at: http://www.livescience.com/health/obesity-lowers-testosterone-100503.html. Accessed June 23, 2010.
6. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 Mar;6(1):1-7.
7. Lunenfeld B. Testosterone deficiency and the metabolic syndrome. Aging Male. 2007 Jun;10(2):53-6.
8. Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007 Mar;92(3):1049-57.
9. Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab. 2006 Jul;8(4):429-35.
10. Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses. 2008;70(2):358-60.
11. Zumoff B. Hormonal abnormalities in obesity. Acta Med Scand Suppl. 1988;723:153-60.
12. Diaz-Arjonilla M, Schwarcz M, Swerdloff RS, Wang C. Obesity, low testosterone levels and erectile dysfunction. Int J Impot Res. 2009 Mar-Apr;21(2):89-98.
13. Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol. 2006 Oct;176(4 Pt 1):1524-7; discussion 27-8.
14. Schubert M, Jockenhovel F. Testosterone and the metabolic syndrome. Urologe A. 2010 Jan;49(1):47-50.
15. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979-83.
16. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 2005 Jun 1;23(16):3718-25.
17. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005 Sep;174(3):827-34.
18. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005 May;90(5):2618-23.
19. Corrales JJ, Burgo RM, Garca-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004 May;53(5):666-72.
20. Anawalt BD, Merriam GR. Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metab Clin North Am. 2001 Sep;30(3):647-69.
21. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010 May;64(6):682-96.
22. Tong PC, Ho CS, Yeung VT, et al. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab. 2005 Dec;90(12):6418-23.
23. Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia. 2008 Aug;40(4):259-64.
24. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005 Sep;63(3):239-50.
25. Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res. 2009;37:74-90.
26. Rice D, Brannigan RE, Campbell RK, et al. Men’s health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach. Diabetes Educ. 2008 Nov-Dec;34 Suppl 5:97S-112S; quiz 13S-4S.
27. Saad F. The role of testosterone in type 2 diabetes and metabolic syndrome in men. Arq Bras Endocrinol Metabol. 2009 Nov;53(8):901-7.
28. Chubb SA, Hyde Z, Almeida OP, et al. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol. 2008 Jun;158(6):785-92.
29. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S, Mohanty P. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med. 2008 Dec;8(8):816-28.
30. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl. 2009 Jan-Feb;30(1):23-32.
31. Rabijewski M, Papierska L, Kozakowski J, Zgliczynski W. The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men. Endokrynol Pol. 2007 Nov-Dec;58(6):496-504.
32. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004 May;6(3):208-15.
33. Blouin K, Despres JP, Couillard C, et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism. 2005 Aug;54(8):1034-40.
34. Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003 Dec;149(6):601-8.
35. Goncharov NP, Katsya GV, Chagina NA, Gooren LJ. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone. Aging Male. 2008 Sep;11(3):118-22.
36. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009 Nov-Dec;30(6):726-33.
37. Saad F, Gooren L, Haider A, Yassin A. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia. 2008 Feb;40(1):44-8.
38. Morgentaler A. Rapidly shifting concepts regarding androgens and prostate cancer. ScientificWorldJournal. 2009;9:685-90.
39. Gotay CC. Cancer prevention: major initiatives and looking into the future. Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):143-54.
40. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010 May;101(5):1073-9.